Test News

Lee 2023/04/11 S2 Import: post title expands when hover

Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy

August 22, 2022

Asieris on Science and Technology Innovation Board “2022 Most Innovative Companies” List

August 11, 2022

Now Hiring: Business Development Director (Remote)

August 11, 2022

Now Hiring: Biomarker Scientist (Onsite, Mountain View)

August 11, 2022

Now Hiring: Protein Scientist (Onsite, Mountain View)

August 11, 2022

Now Hiring: Bioinformatics Scientist (Onsite, Mountain View)

August 11, 2022

Now Hiring: Research Associate or Sr. RA (Onsite, Mountain View)

August 10, 2022

Asieris Appoints Dr. Badrinath Konety to Scientific Advisory Board

August 9, 2022

Asieris’ Multinational Phase III Clinical Trial for the Non-Surgical Treatment of HSIL Has Completed Enrollment

August 8, 2022

The First Domestic Case in Boao, Ushering in a New Option for Diagnosing Bladder Cancer

June 9, 2022

Asieris to publish the study protocol of Cevira® as a novel treatment in patients with high grade squamous intraepithelial lesion (HSIL) on BMJ Open

June 5, 2022

2022 ASCO, Asieris Presented a Study Protocol of Muscle Invasive Bladder Cancer(MIBC)

May 27, 2022

Asieris to present a study protocol of APL-1202 in combination with BeiGene’s tislelizumab as neoadjuvant therapy (NAC) for muscle invasive bladder cancer (MIBC) patients at 2022 ASCO annual meeting

April 27, 2022

Asieris Pharmaceuticals 2022 Q1 Quarterly Report

April 15, 2022

Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy

March 28, 2022

Now Hiring: Lab Manager (San Francisco)

March 26, 2022

Now Hiring: Head of Toxicology, Director to Senior Director (Shanghai or San Francisco)

March 11, 2022

Hexvix® Has Obtained CDE Approval to Carry Out Clinical Real-World Evidence Study

February 24, 2022

Now Hiring: Clinical Pharmacologist

February 24, 2022

Now Hiring: Research Associate / Senior Research Associate

February 16, 2022

Asieris to Increase Presence at ASCO GU 2022

February 11, 2022

Hexvix® Has Obtained the Approval from the NMPA for Phase Ⅲ Clinical Trial

February 1, 2022

Now Hiring: Lab & Office Manager (San Francisco)

January 27, 2022

Now Hiring: Scientist / Senior Scientist (San Francisco)

January 7, 2022

Asieris Pharmaceuticals Lands on STAR Market

January 4, 2022

World’s First Patient Dose Administered in Combination of Asieris’ APL-1202 and BeiGene’s Tislelizumab as Neoadjuvant Therapy for MIBC Patients

Lee: Note post titles in all lists of this tab structure all shrink instead of expand!

2023

2022

2021

2020

2019

2023

2022

2021

2020

2019

Lee 2023/04/11 S2 Import: post title expands when hover

Lee: Note post titles in all lists of this tab structure all shrink instead of expand!

APL-2301, a FIC small molecule developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia

Asieris Successfully Convenes First Domestic Breast Cancer Care Forum and National Product Launch Conference for Ouyoubi in Shanghai

Two Asieris Studies in the Field of Bladder Cancer Selected for Oral and Poster Presentations at the 2024 American Society of Clinical Oncology Genitourinary Cancer Symposium, Potentially Offering New Disease Management Options for Patients

Asieris announces NMPA has accepted the New Drug Application for APL-1706, an Imaging Drug for Diagnosing and Management of Bladder Cancer

Asieris’First Product Dipaite Achieves Commercialization and Launches in China, First Prescription Issued in Shanghai

Asieris Unveiled Results of Its Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the SIU 2023 Congress

Asieris to Unveil First-ever Results of the Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the 2023 SIU Annual Meeting

The First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

Asieris’ New Drug APL-1401 Completes First Administration in Patient with Moderately to Severely Active UC

Asieris Announces Positive Interim Analysis Results in Phase II Clinical Trial of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer

Asieris Obtained IND Approval from NMPA for APL-1401, a Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization

Highlights of Asieris Pharmaceuticals 2023 Semi-Annual Report

Hong Kong Department of Health has Approved the Registration Applications for the Uro-G and Uro-V Disposable Cystoscopic System

Asieris Announces Positive Result from Phase III Bridging Trial of Hexvix®, a Diagnostic Drug for Bladder Cancer

Asieris has completed the China Phase III Bridging Trial Enrollment of Hexvix®, a Diagnostic Drug for Bladder Cancer

Asieris’ progress in MIBC receives renewed attention with its inclusion in ASCO 2023

Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer

Asieris Releases 2022 Annual Report: Make Steady Progress in its Clinical Development, Global Expansion to Treat Genitourinary Tumors, and Implementing its Commercialization Strategy to Provide Integrated Diagnosis-to-Treatment Solutions

Highlights of Asieris Pharmaceuticals 2022 Annual Report

Asieris’ subsidiary makes significant progress in its commercialization strategy by obtaining the “Drug Distribution License”

NMPA accepted the registration applications for Uro-G and Uro-3500

Asieris Drug Plays Pivotal Role to Help UCSF Save a Life

Asieris and ReviR Enter into Research Collaboration Agreement to Discover Oncology Therapeutics Based on ReviR’s Comprehensive Approach to RNA-targeting Technologies

Asieris Appoints Dr. Linda Wu as Chief Development Officer